Age
Item
age ≥18 years on the day of the first prescription of the study drug (= index date) during study selection window
boolean
C0001779 (UMLS CUI [1])
Atrial Fibrillation | Heart Valves
Item
diagnosis of nvaf on start date of study or anytime during 365 days before this date
boolean
C0004238 (UMLS CUI [1])
C0018826 (UMLS CUI [2])
Availability of follow-up | Investigational New Drugs
Item
availability of follow-up at least 180 days after the date of the first prescription of study drug within selection window of study (exposure start date)
boolean
C0470187 (UMLS CUI [1,1])
C1522577 (UMLS CUI [1,2])
C0013230 (UMLS CUI [2])
Evidence of Patient activity
Item
evidence of patient activity in the database during 90 days before the date of the first prescription of target drug within selection window.
boolean
C0332120 (UMLS CUI [1,1])
C0451369 (UMLS CUI [1,2])
Atrial Fibrillation | Heart Valves
Item
patients with valvular af
boolean
C0004238 (UMLS CUI [1])
C0018826 (UMLS CUI [2])
oral anticoagulants | Vitamin K antagonists | dabigatran | rivaroxaban
Item
prescriptions of oral anticoagulants (oacs: vka, dabigatran, rivaroxaban) before index date
boolean
C0354604 (UMLS CUI [1])
C3653316 (UMLS CUI [2])
C2348066 (UMLS CUI [3])
C1739768 (UMLS CUI [4])
Other oral anticoagulants
Item
prescription of more than one oac on the index date or switch to another oac during the follow-up period
boolean
C0205394 (UMLS CUI [1,1])
C0354604 (UMLS CUI [1,2])
rivaroxaban | cohort
Item
prescriptions of < 15mg rivaroxaban at index date or during the follow-up period for patients in rivaroxaban cohort
boolean
C1739768 (UMLS CUI [1])
C0599755 (UMLS CUI [2])